193 related articles for article (PubMed ID: 15552270)
1. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma.
Alexandrakis MG; Passam FJ; Ganotakis E; Dafnis E; Dambaki C; Konsolas J; Kyriakou DS; Stathopoulos E
Clin Chem Lab Med; 2004; 42(10):1122-6. PubMed ID: 15552270
[TBL] [Abstract][Full Text] [Related]
2. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
[TBL] [Abstract][Full Text] [Related]
3. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
4. Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density.
Alexandrakis MG; Passam FH; Pappa CA; Damilakis J; Tsirakis G; Kandidaki E; Passam AM; Stathopoulos EN; Kyriakou DS
Int J Immunopathol Pharmacol; 2005; 18(2):287-95. PubMed ID: 15888251
[TBL] [Abstract][Full Text] [Related]
5. Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma.
Tsirakis G; Pappa CA; Kanellou P; Stratinaki MA; Xekalou A; Psarakis FE; Sakellaris G; Alegakis A; Stathopoulos EN; Alexandrakis MG
Hematol Oncol; 2012 Sep; 30(3):131-6. PubMed ID: 21919032
[TBL] [Abstract][Full Text] [Related]
6. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
9. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma.
Kara IO; Sahin B; Gunesacar R; Unsal C
Adv Ther; 2006; 23(4):635-45. PubMed ID: 17050506
[TBL] [Abstract][Full Text] [Related]
11. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
12. Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.
Kokonozaki M; Tsirakis G; Devetzoglou M; Kyriakaki S; Antonakis A; Vyzoukaki R; Pappa CA; Tzardi M; Alexandrakis MG
Leuk Res; 2015 Dec; 39(12):1467-72. PubMed ID: 26521986
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis in multiple myeloma.
Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia.
Zhelyazkova AG; Tonchev AB; Kolova P; Ivanova L; Gercheva L
Scand J Clin Lab Invest; 2008; 68(6):492-500. PubMed ID: 18609087
[TBL] [Abstract][Full Text] [Related]
16. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant.
Sucak GT; Aki SZ; Yüzbaşioğlu B; Akyürek N; Yağci M; Bağriaçik U; Haznedar R
Leuk Lymphoma; 2011 Jul; 52(7):1281-9. PubMed ID: 21599578
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
[TBL] [Abstract][Full Text] [Related]
19. Expression of proliferating cell nuclear antigen (PCNA) in multiple myeloma: its relationship to bone marrow microvessel density and other factors of disease activity.
Alexandrakis MG; Passam FH; Pappa CA; Dambaki C; Sfakiotaki G; Alegakis AK; Kyriakou DS; Stathopoulos E
Int J Immunopathol Pharmacol; 2004; 17(1):49-56. PubMed ID: 15000866
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Sezer O; Jakob C; Eucker J; Niemöller K; Gatz F; Wernecke K; Possinger K
Eur J Haematol; 2001 Feb; 66(2):83-8. PubMed ID: 11168514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
